Minesh P. Mehta, MD
Professor, Department of Human Oncology
School of Medicine and Public Health
University of Wisconsin
Mark R. Gilbert, MD
Professor and Deputy Chair
Department of Neuro-Oncology
University of Texas MD Anderson Cancer Center
Arnab Chakravarti, MD
Associate Professor, Radiation Oncology
Director, Laboratory of Molecular and Cellular Radiation Neuro-Oncology
Massachusetts General Hospital
Harvard Medical School
Physician CME: 1.0
Nurse CE: 0.1 CEU Medium
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIANS AND NURSES, ONLY
This conversation between two radiation oncologists and a neuro-oncologist explores a few of most intriguing topics in the management of patients with primary malignant gliomas. These revolve around the concept of tailoring treatments to the unique biology of the patientís tumor in hopes of yielding better outcomes. Although primary gliomas represent a small percentage of cancers, they continue to pose a large clinical challenge. Surgical resection, while beneficial, is never curative and conventional treatment, such as radiotherapy, only delays tumor regrowth. Therefore, the prognosis remains bleak for the majority of primary glioma patients. However, newer treatment combinations and recent biomarker discoveries are yielding improved time-to-progression and survival rates.
Discussion topics were selected from content covered in an ongoing CME/CE-accredited educational Grand Rounds series presented throughout the United States in 2007. Program Developer/Facilitator
. Target Audience
This enduring material program, developed by experts in radiation- and neuro-oncology, has been specially designed for physicians and advance practice nurses who interact with oncology patients.
Upon completion of this educational activity, the participant should be able to:
Discuss the importance of molecular biomarkers in identifying prognostic variables.
Review the clinical trial evidence that led to defining combination chemoradiotherapy as the new standard of care for some malignant gliomas.
Explain the advantages and limitations of systemic and intraoperative chemotherapeutic treatments for primary malignant gliomas.
Describe patient management issues relevant to the care of patients with primary gliomas.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Gilbert discloses that he serves on a speakersí bureau for Schering-Plough and advisory committees for Genentech and Schering-Plough.
Dr. Mehta discloses that he serves on an advisory committee for Allos and as a product consultant for Pharmacyclics. He is also on a speakersí bureau for Schering-Plough Corporation.
Dr. Chakravarti discloses that he has no actual or potential conflict of interest to this program.
This educational activity contains discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Centerís Commission on Accreditation.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU).
This activity should take approximately 60 minutes to complete.
Commercial Support Statements
This activity is supported by an educational grant from Schering-Plough.
©2007 Medical Communications Media, Inc. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patientsí conditions, considering possible contraindications or risks, reviewing any applicable manufacturerís product information, and comparing any therapeutic approach with the recommendations of other authorities.